Table 3

Observed number of cases or deaths and standardised incidence ratios (SIRs) or standardised mortality ratios (SMRs) with 95% CIs for selected cancer sites in men in the Norwegian Fire Departments Cohort, stratified by period of follow-up (n=4295)

Cancer siteICD-10Period of follow-up
≤1984 (35 977 pyr)1985–1994 (21 017 pyr)≥1995 (60 464 pyr)
Obs.Ratio95% CIObs.Ratio95% CIObs.Ratio95% CI
All cancers, SIRC00-C971511.201.01 to 1.401511.181.00 to 1.396141.131.05 to 1.23
All cancers, SMRC00-C97921.261.01 to 1.54771.140.90 to 1.422071.000.87 to 1.15
Oesophagus, SIRC15<51.970.41 to 5.76<51.490.18 to 5.3791.460.67 to 2.76
Oesophagus*, SMRC15<52.150.44 to 6.27<51.620.20 to 5.8691.760.81 to 3.35
Stomach, SIRC16161.350.77 to 2.20101.520.73 to 2.80151.230.69 to 2.02
Stomach, SMRC16131.340.71 to 2.2991.740.79 to 3.2980.900.39 to 1.78
Colon, SIRC18171.961.14 to 3.15161.500.86 to 2.43491.090.80 to 1.44
Colon, SMRC18112.351.17 to 4.2191.660.76 to 3.15150.790.44 to 1.30
Rectum, rectosigmoid, SIRC19-C2150.720.24 to 1.6960.800.29 to 1.73311.140.78 to 1.62
Rectum, rectosigmoid, SMRC19-C21<50.820.17 to 2.38<50.530.06 to 1.90161.730.99 to 2.80
Liver, gallbladder, bile ducts, SIRC22-C2463.971.46 to 8.64<52.040.42 to 5.9660.870.32 to 1.89
Liver, gallbladder, bile ducts*, SMRC22-C2453.461.12 to 8.08<52.650.55 to 7.7561.190.44 to 2.59
Larynx, SIRC32<50.540.01 to 3.0353.311.08 to 7.7371.750.70 to 3.61
Larynx, SMRC32<51.710.04 to 9.52<52.200.06 to 12.3<52.460.51 to 7.20
Lung, SIRC33-C34191.150.69 to 1.79221.330.83 to 2.01500.890.66 to 1.17
Lung, SMRC33-C34151.070.60 to 1.76191.310.79 to 2.04330.750.51 to 1.05
Cutaneous melanoma, SIRC4351.150.37 to 2.69111.950.97 to 3.48341.160.81 to 1.63
Cutaneous melanoma, SMRC43<51.300.16 to 4.69<52.630.72 to 6.7471.170.47 to 2.40
Non-melanoma skin†, SIRC44<51.050.22 to 3.08<50.560.12 to 1.64311.030.70 to 1.46
Non-melanoma skin†, SMRC4400.000.00 to 14.900.000.00 to 16.8<51.330.03 to 7.39
Mesothelioma, SIRC45<53.880.10 to 21.600.000.00 to 5.7173.041.22 to 6.26
Mesothelioma*, SMRC45<50<52.220.60 to 5.68
Prostate, SIRC61150.810.45 to 1.33341.320.91 to 1.841821.201.03 to 1.39
Prostate, SMRC6170.970.39 to 1.9970.650.26 to 1.33411.130.81 to 1.53
Testis, SIRC62<51.530.42 to 3.9200.000.00 to 1.27141.680.92 to 2.82
Testis, SMRC6200.000.00 to 4.8300.000.00 to 23.500.000.00 to 9.63
Kidney‡, SIRC64<50.980.27 to 2.5292.511.15 to 4.77191.130.68 to 1.76
Kidney‡**, SMRC64<50.390.01 to 2.1752.320.75 to 5.4160.930.34 to 2.02
Urinary tract§, SIRC65-C68151.500.84 to 2.48161.460.83 to 2.37421.080.78 to 1.46
Urinary tract§, SMRC65-C68<51.100.23 to 3.2151.830.59 to 4.2780.920.40 to 1.81
Thyroid, SIRC73<51.120.03 to 6.2600.000.00 to 4.7151.680.55 to 3.93
Thyroid, SMRC73<54.210.11 to 23.500.000.00 to 17.0<52.060.05 to 11.5
Hodgkin lymphoma, SIRC8100.000.00 to 2.2100.000.00 to 4.97<50.930.11 to 3.35
Hodgkin lymphoma, SMRC81<51.170.03 to 6.5100.000.00 to 14.600.000.00 to 8.70
non-Hodgkin's lymphoma, SIRC82-C86, C96<50.950.20 to 2.7771.860.75 to 3.84170.990.58 to 1.59
non-Hodgkin's lymphoma, SMRC82-C86, C96<50.540.01 to 3.04<50.940.11 to 3.4060.980.36 to 2.12
Multiple myeloma, SIRC90<51.280.26 to 3.73<50.960.12 to 3.4550.640.21 to 1.49
Multiple myeloma, SMRC90<51.250.15 to 4.51<51.900.39 to 5.56<50.650.13 to 1.91
Leukaemia, SIRC91-C95<51.090.30 to 2.78<50.350.01 to 1.96100.860.41 to 1.58
Leukaemia, SMRC91-C95<51.330.36 to 3.40<50.520.01 to 2.9171.190.48 to 2.45
  • Cells lacking SMR had 0 expected deaths.

  • Follow-up from 1 January 1960 to 31 December 2018.

  • *Observed number of deaths corrected to be in line with morphologically confirmed diagnoses, as described in the text (Results, paragraph 3–6).

  • †Excluding basal cell carcinoma.

  • ‡Excluding renal pelvis.

  • §Including bladder and renal pelvis.

  • ICD, International Classification of Diseases; Obs., observed; pyr, person-years.